Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant AGS-003 in Localized Kidney Cancer
NCT02170389Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Oct 2014
- Primary completion
- Mar 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of rocapuldencel-T in renal cell carcinoma (RCC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Change in Immune Marker Expression Levels. Started Oct 2014; status: terminated.
02
Drugs
rocapuldencel-T
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02170389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170389.